# Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients

> **NCT03254966** · PHASE2 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 194 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** SHR0302
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03254966
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-24
- **Primary completion:** 2019-04-16
- **Final completion:** 2019-10-12
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2021-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03254966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03254966, "Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03254966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*